Literature DB >> 24798973

Inhibition of macrophage polarization prohibits growth of human osteosarcoma.

Qiang Xiao1, Xuepu Zhang, Yuexin Wu, Yu Yang.   

Abstract

Osteosarcoma is the most malignant bone tumor characterized by high local aggressiveness and poor therapeutic outcome. Tumor-associated macrophages (TAM) have been shown to participate in the development and progress of many types of cancer cells. However, whether TAM may play a role in the pathogenesis of osteosarcoma is largely unknown. In a mouse model of human osteosarcoma implantation, we showed that the recruited macrophages at the site of the implanted tumor were polarized to an M2 subtype (same as TAM) during the development and growth of the osteosarcoma. In a loss-of-function experiment, we deleted these TAM with a specific macrophage-eliminating liposome, which resulted in decreased tumor growth. Moreover, when the epidermal growth factor receptor (EGFR) in the implanted cancer cells was inhibited by shRNA, the tumor failed to grow in response to the recruited macrophages. Taken together, for the first time, we show that the growth of an osteosarcoma is EGFR signaling-dependent and TAM-mediated. Our data suggest that TAM and EGFR may be good targets for treating human osteosarcoma.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24798973     DOI: 10.1007/s13277-014-2005-y

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  19 in total

Review 1.  Macrophage plasticity and polarization: in vivo veritas.

Authors:  Antonio Sica; Alberto Mantovani
Journal:  J Clin Invest       Date:  2012-03-01       Impact factor: 14.808

Review 2.  Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm.

Authors:  Subhra K Biswas; Alberto Mantovani
Journal:  Nat Immunol       Date:  2010-09-20       Impact factor: 25.606

3.  Caffeine-assisted chemotherapy and minimized tumor excision for nonmetastatic osteosarcoma.

Authors:  H Tsuchiya; K Tomita; Y Mori; N Asada; T Morinaga; S Kitano; N Yamamoto
Journal:  Anticancer Res       Date:  1998 Jan-Feb       Impact factor: 2.480

4.  Two established in vitro cell lines from human mesenchymal tumours.

Authors:  J Pontén; E Saksela
Journal:  Int J Cancer       Date:  1967-09-15       Impact factor: 7.396

Review 5.  Development of monocytes, macrophages, and dendritic cells.

Authors:  Frederic Geissmann; Markus G Manz; Steffen Jung; Michael H Sieweke; Miriam Merad; Klaus Ley
Journal:  Science       Date:  2010-02-05       Impact factor: 47.728

Review 6.  Macrophage diversity in renal injury and repair.

Authors:  Sharon D Ricardo; Harry van Goor; Allison A Eddy
Journal:  J Clin Invest       Date:  2008-11       Impact factor: 14.808

7.  Elimination of phagocytic cells in the spleen after intravenous injection of liposome-encapsulated dichloromethylene diphosphonate. An enzyme-histochemical study.

Authors:  N van Rooijen; R van Nieuwmegen
Journal:  Cell Tissue Res       Date:  1984       Impact factor: 5.249

Review 8.  Clodronate.

Authors:  J A Kanis; E V McCloskey
Journal:  Cancer       Date:  1997-10-15       Impact factor: 6.860

Review 9.  New molecular insights into osteosarcoma targeted therapy.

Authors:  Jilong Yang; Wei Zhang
Journal:  Curr Opin Oncol       Date:  2013-07       Impact factor: 3.645

Review 10.  Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  G L Plosker; K L Goa
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

View more
  17 in total

1.  Enhanced Wnt signaling by methylation-mediated loss of SFRP2 promotes osteosarcoma cell invasion.

Authors:  Qiang Xiao; Yu Yang; Xuepu Zhang; Qing An
Journal:  Tumour Biol       Date:  2015-12-01

Review 2.  Tissue-engineered models of human tumors for cancer research.

Authors:  Aranzazu Villasante; Gordana Vunjak-Novakovic
Journal:  Expert Opin Drug Discov       Date:  2015-02-07       Impact factor: 6.098

3.  TIPE1 suppresses osteosarcoma tumor growth by regulating macrophage infiltration.

Authors:  P Chen; J Zhou; J Li; Q Zhang; Q Zuo
Journal:  Clin Transl Oncol       Date:  2018-07-30       Impact factor: 3.405

4.  Shikonin inhibits invasiveness of osteosarcoma through MMP13 suppression.

Authors:  Biyong Deng; Bing Qiu
Journal:  Tumour Biol       Date:  2015-06-24

5.  Overexpression of miR-100 inhibits growth of osteosarcoma through FGFR3.

Authors:  Yunlong Bi; Yu Jing; Yang Cao
Journal:  Tumour Biol       Date:  2015-05-29

6.  Tumor-associated macrophages in osteosarcoma.

Authors:  Yi Zhao; Benzheng Zhang; Qianqian Zhang; Xiaowei Ma; Helin Feng
Journal:  J Zhejiang Univ Sci B       Date:  2021-11-15       Impact factor: 3.066

Review 7.  Immune Microenvironment in Osteosarcoma: Components, Therapeutic Strategies and Clinical Applications.

Authors:  Tianyi Zhu; Jing Han; Liu Yang; Zhengdong Cai; Wei Sun; Yingqi Hua; Jing Xu
Journal:  Front Immunol       Date:  2022-06-01       Impact factor: 8.786

8.  TIPE2 regulates tumor-associated macrophages in skin squamous cell carcinoma.

Authors:  Xin Li
Journal:  Tumour Biol       Date:  2015-11-15

9.  Overexpression of miR-506 inhibits growth of osteosarcoma through Snail2.

Authors:  Zhongxiang Yu; Yuting Zhang; Ningyang Gao; Xiang Wang
Journal:  Am J Transl Res       Date:  2015-12-15       Impact factor: 4.060

10.  Dysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma.

Authors:  Clotilde Dumars; Jean-Michel Ngyuen; Aurélie Gaultier; Rachel Lanel; Nadège Corradini; François Gouin; Dominique Heymann; Marie-Françoise Heymann
Journal:  Oncotarget       Date:  2016-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.